Triple-drug regimen lowers A1C, treatment failure in new-onset diabetes

10/8/2013 | InternalMedicineNews.com (free registration)

Patients with new-onset type 2 diabetes who had initial triple-drug treatment of metformin, exenatide and pioglitazone attained a mean A1C of 5.9% at two years, compared with 6.6% in those who received conventional stepwise treatment, a study indicated. Researchers also found the triple-drug regimen was associated with an 84% reduction in two-year treatment failure rates compared with standard therapy. The results were presented at the European Association for the Study of Diabetes meeting.

View Full Article in:

InternalMedicineNews.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN